A multicenter randomized controlled study of the effects of wide-chest aerosol on anxiety and depression in patients with coronary heart disease after PCI

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077163

Enrollment

Unknown

Registered

2023-11-01

Start date

2023-11-01

Completion date

Unknown

Last updated

2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety and depression after PCI of coronary heart disease

Interventions

Observation group:All patients received routine treatment from the hospital's medical staff. These include predictive drugs (aspirin, beta-blockers, statins, ACEI), symptom-improving drugs (nitrates,

Placebo group:All patients received routine treatment from the hospital's medical staff. These include predictive drugs (aspirin, beta-blockers, statins, ACEI), symptom-improving drugs (nitrates, calc

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients meet the diagnostic criteria for coronary heart disease; (2) Patients underwent PCI surgery, and it was not more than 3 days from the day of enrollment; (3) Hamilton Depression Scale (HAMA) score = 7 or Hamilton Anxiety scale (HAMD) score = 7; (4) Aged between 20 and 70 years old. (4) Clear consciousness, good language communication ability, and understanding ability; (5) Sign the informed consent, voluntarily join the study, and be able to complete the entire research plan.

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) patients with unstable vital signs; (2) Acute inflammation, acute kidney failure, acute heart failure, and other acute diseases; (3) The patient is participating in other drug trials or other psychosocial intervention studies at the same time; (4) Patients with obvious anxiety and depression, HAMA score =7 or HAMD score =7 and mental illness were found before surgery; (5) Patients taking antipsychotic drugs or sedative sleeping drugs (such as olanzapine, Suloxam, Synox, etc.); (6) Patients who have received any other antidepressant or anxiety treatment within the last 3 months; (7) Previous history of depression, history of organic brain changes, history of taking some psychoactive substances, etc. (8) have severe hearing or cognitive speech impairment; (9) Pregnant or lactation, or planned pregnancy patients.

Design outcomes

Primary

Measure	Time frame
Assessment of anxiety state;Assessment of depressive status;	—

Secondary

Measure	Time frame
Quality of life evaluation after PCI;electroencephalogram;	—

Countries

China

Contacts

Public ContactXingwei Zhang

Affiliated Hospital of Hangzhou Normal University

xwzhang@hznu.edu.cn+86 139 5718 6455

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026